APTX News and Press, Aptinyx Inc. From 05/17/22

Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that data from preclinical studies of NYX-783 in models of post-traumatic stress disorder (PTSD) will be p...

Aptinyx, Inc. (APTX) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants Pat Flavin - IR Andy Kidd - CEO Ashish Khanna - CFO Kathryn King - SVP of Clinical and CMC operations Harald Murck - VP of Medical and Clinical Affairs Conference Call Participants Ritu Baral - ...

Image source: The Motley Fool. Aptinyx Inc. (NASDAQ: APTX) Q1 2022 Earnings Call May 12, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Aptinyx Inc. (APTX) Q1 2022 Earnings Call Transcript

Aptinyx press release (NASDAQ:APTX): Q1 GAAP EPS of -$0.29 beats by $0.01. Cash and cash equivalents were $100.2 million at March 31, 2022, compared to $106.1 million at December 31, 2021. Aptinyx expects its current cash balance to support anticipated operations into 2024. For further deta...

Current cash position of > $100 million expected to fund operations into 2024 and enable readouts from all three ongoing Phase 2 studies Data readout from Phase 2b study of NYX-2925 in fibromyalgia expected in early to mid 3Q 2022 Data readout from exploratory Phase...

AAIC, ACB, ACHV, AFRM, AGRO, AGRX, APDN, APTX, AQN, AVPT, AXU, BANX, BBI, BEAT, BIOL, BLBD, BLND, BOXL, BSQR, CBAY, CDXC, CLLS, CLVR, CODX, COMP, CORZ, CRMD, CTIC, CURI, CWCO, DARE, DUOL, EDR, ETON, EYEN, FIGS, GPL, GWH, HLI, HTGM, IBIO, IDN, OTCQB:IGXT, IMMR, INDI, INTZ, INUV, JOBY, KMPH, LC...

Aptinyx (NASDAQ:APTX) is scheduled to announce Q1 earnings results on Wednesday, May 11th, after market close. The consensus EPS Estimate is -$0.31 and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 5 upward revisions and 0 downward. For further detail...

Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today presented data from preclinical studies of NYX-783 in models of post-traumatic stress disorder (PTSD) at the Society...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, May 12, 2022 at 5:00 p.m. ET to...

Preclinical data support the continued clinical development of NYX-783 as a novel mechanistic approach for treating post-traumatic stress disorder (PTSD) NYX-783 is currently under evaluation in a Phase 2b study in patients with PTSD Aptinyx Inc. (Nasdaq: APTX), a cl...